Advances in Single-Cell Sequencing Technology and Its Applications in Triple-Negative Breast Cancer
Meng Li,Tingting Yan,Miaozhou Wang,Yanqiu Cai,Yingyuan Wei
DOI: https://doi.org/10.2147/BCTT.S388534
2022-12-14
Breast Cancer: Targets and Therapy
Abstract:Meng Li, Tingting Yan, Miaozhou Wang, Yanqiu Cai, Yingyuan Wei Graduate School of Qinghai University, Qinghai University, Xining, Qinghai Province, People's Republic of China Correspondence: Miaozhou Wang, Email Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and is mainly treated with chemotherapy-based combination therapy. In recent years, with the increasing development of global precision medicine, single-cell sequencing (SCS) has become one of the most promising technologies in the field of biotechnology. Moreover, the related application of this technology in TNBC has been applied and developed. By using SCS to study the heterogeneity of TNBC tumor cells, metastasis, drug resistance mechanisms, mutations, and cloning; it can further guide clinical chemotherapy, targeted therapy, and immunotherapy. To further reflect the importance of SCS in TNBC, this paper elaborated on and summarized the research and application progress of SCS in TNBC. Keywords: TNBC, SCS, heterogeneity, drug resistance, metastasis Breast cancer (BC) can be classified into four subtypes according to pathology: Luminal A, Luminal B, HER2-positive, and TNBC. 1 Among these, TNBC is characterized by the absence of corresponding hormone receptors, and this type accounts for approximately 12–17% of all BC pathological subtypes. 2 Studies have shown that the 5-year survival rate of patients with TNBC is only 77% and 93% for other types, which is lower compared with other types of BC. 3 TNBC is a disease entity characterized by extensive inter-and intra-tumor heterogeneity, and likely represents multiple clinically and biologically distinct subgroups that have not been clearly defined. 4,5 The majority of TNBCs share common histological and molecular features including frequent p53 mutations, a high proliferation index, and frequent expression of basal-like gene expression signature. 6 These signatures make TNBC exhibit significant angiogenesis and epithelial-mesenchymal (EMT), which makes tumor cells more aggressive, and prone to recurrence and metastasis, with a relatively poor recovery. 7 Therefore, there is an urgent need to use emerging technologies to discover new strategies regarding the treatment of TNBC, in which the study of TNBC from the single-cell level is the focus of our research. In recent years, with the continuous development of high-throughput sequencing technology, SCS has been widely used in various research fields and various cell types. Using SCS at the cellular on the target analysis provides a comprehensive understanding of the genome, transcriptome, and epigenetic property. Thus, we can fully and effectively recognize the unique phenotypes produced by individual cells and provides a powerful tool to address the heterogeneity of tumor cells, detect related subtypes and reconstruct evolutionary lineage, Therefore, which can provide a reliable basis for the precise treatment of TNBC. 8,9 SCS is a technique that reveals the genome, transcriptome, or epigenetic changes of cells at the level of single cells, revealing the functions and characteristics of cells from different perspectives. Information of hundreds or thousands of single cells can be measured through database construction at a time. Human research on single cells is mainly based on sequencing technologies (first-generation sequencing, second-generation sequencing, and third-generation sequencing). The first-generation sequencing technology, namely the Sanger sequencing method, developed by Frederick Sanger et al in 1997, focuses on the calibration of bases of single nucleic acid molecules for sequencing purposes, and the result of this technology draws a preliminary sketch of a human gene sequence in 2003, laying the foundation for decoding of life. In 2000, second-generation sequencing (high-throughput parallel sequencing) was developed to further decode cellular and molecular changes from single-cell transcriptome, genome, epigenetics, and combined multi-omics single-cell sequencing technologies, thus providing a good platform for medical research progress. The sequencing data obtained by traditional high-throughput sequencing technology is only the average gene determination of a mixed collection of cells from a large number of tissue samples. Compared with traditional sequencing technology, SCS not only accurately measures gene expression levels and detects trace expression of non-coding RNA, but also can give full play to the advantages of sequencing special samples and make up for the shortcomings of special samples due to small sample size and not easy to obtain. 10,11 The technical process of SCS mainly includes single-cell isolation and acquisition, genome/transcriptome/epigenome library construction, gene sequencing, and d -Abstract Truncated-
English Else